FUNDING SIGNALS

Real Signals. Real Leads. Real Deals.

The only platform that turns real-time signals into your perfect leads

Know Who, Why, and When to reach out — instantly.

FundzWatch™ AI Scoring

10-25 leads daily

Real-time alerts

★★★★★

4.8/5 on G2• High Performer Fall 2025

Used by teams at LinkedIn, HubSpot & Oracle

🔒 app.fundz.net

TechCorp

📍 San Francisco👥 85

Post-Funding

⭐ Ideal Match

Just raised $40M Series B - high purchase intent window

Qlaris Bio, Inc. announced it raised $8.16 Million in an initial filing from an offering of $27.3 Million

Aug 28, 2019•about 6 years ago

Amount Raised

$8.16 Million

DedhamBiotechnology

Company Information

Company

Qlaris Bio, Inc.

Location

770 Legacy Place

Dedham, Massachusetts, United States

About

At Qlaris, our lead program is QLS-111, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-111 is distinct from currently available therapies by selectively targeting episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the improved treatment of diseases where EVP has limited therapy or has itself been pathologic, such as Normal Tension Glaucoma, Primary Open Angle Glaucoma, glaucoma associated with Sturge-Weber Syndrome, and also in combination with Minimally-Invasive Glaucoma Surgery (MIGS) devices.

Company News

(9 articles)

Wed, 11 Jun 2025 07:00:00 GMT

Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma - Business Wire

Tue, 26 Aug 2025 07:00:00 GMT

Qlaris Bio Announces First Patient Dosed in Phase II Nightingale Clinical Trial in Normal Tension Glaucoma Patients - Yahoo Finance

Thu, 26 Jun 2025 07:00:00 GMT

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress - Ophthalmology Times

Mon, 23 Jun 2025 07:00:00 GMT

Qlaris Bio to Present New Clinical and Preclinical Data on QLS-111 at 2025 World Glaucoma Congress - Business Wire

Tue, 26 Aug 2025 07:00:00 GMT

First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111 - Optometry Times

Mon, 20 Jan 2025 08:00:00 GMT

Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire

Tue, 09 Sep 2025 13:56:00 GMT

Ocular Hypertension Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Bausch + Lomb, Aerie Pharma, Santen Pharma, AbbVie (Allergan), Nicox, Kowa, Qlaris Bio, Noveome Bio - The Globe and Mail

Thu, 18 May 2023 07:00:00 GMT